



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/660,811	09/12/2003	Laurence Rahme	00786/435003	7444
21559 7	590 06/02/2006		EXAM	INER
CLARK & ELBING LLP			DUFFY, PATRICIA ANN	
101 FEDERAL STREET BOSTON, MA 02110			ART UNIT	PAPER NUMBER
			1645	
			DATE MAILED: 06/02/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

• •		Application No.	Applicant(s)			
Office Action Summary		10/660,811	RAHME ET AL.			
		Examiner	Art Unit			
		Patricia A. Duffy	1645			
	The MAILING DATE of this communicati					
	or Reply					
WHII - Exte afte - If NO - Fail Any	HORTENED STATUTORY PERIOD FOR CHEVER IS LONGER, FROM THE MAIL I ensions of time may be available under the provisions of 37 r SIX (6) MONTHS from the mailing date of this communica o period for reply is specified above, the maximum statutory ure to reply within the set or extended period for reply will, but reply received by the Office later than three months after the patent term adjustment. See 37 CFR 1.704(b).	NG DATE OF THIS COMMUNI CFR 1.136(a). In no event, however, may a tion.  y period will apply and will expire SIX (6) MOI y statute, cause the application to become A	CATION. reply be timely filed  NTHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133)			
Status						
1)[]	Responsive to communication(s) filed or	•				
	•	This action is non-final.				
3)	Since this application is in condition for a	ters prosecution as to the merits is				
-,_	closed in accordance with the practice u		•			
Disposit	ion of Claims		,			
		nation				
لکا(⊷	Claim(s) <u>1-26</u> is/are pending in the application.  4a) Of the above claim(s) is/are withdrawn from consideration.					
5)□	Claim(s) is/are allowed.	inidiawii iloili colisideration.				
=	Claim(s) is/are rejected.					
7)	Claim(s) is/are objected to.					
	Claim(s) <u>1-26</u> are subject to restriction a	nd/or election requirement.				
Applicat	ion Papers	·	•			
_		amina.				
	The specification is objected to by the Ex The drawing(s) filed on is/are: a)[		by the Everiner			
10/	Applicant may not request that any objection		-			
	Replacement drawing sheet(s) including the					
11)	The oath or declaration is objected to by					
	under 35 U.S.C. § 119					
_	Acknowledgment is made of a claim for fo	projan priority under 25 U.C.O. (	\$ 110(a) (d) a <sup>1</sup> (b)			
	☐ All b)☐ Some * c)☐ None of:	oreign priority under 35 0.5.C.	3 119(a)-(d) or (f).			
. 4)	1. Certified copies of the priority doc	iments have been received	·			
•	2. Certified copies of the priority doct		upplication No			
	3. Copies of the certified copies of th					
	application from the International E		received in the National Stage			
* (	See the attached detailed Office action for		received.			
		·				
	·					
Attachmen						
	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-9	4) Interview S	Summary (PTO-413) s)/Mail Date			
3) 🔲 Infor	mation Disclosure Statement(s) (PTO-1449 or PTO/	SB/08) 5) D Notice of I	nformal Patent Application (PTO-152)			
Pape	er No(s)/Mail Date	6)  Other:	<u>—</u> ·			

Application/Control Number: 10/660,811

Art Unit: 1645

## DETAILED ACTION

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121: Inventions 1-116.

Claims 1-14, 23 and 24, drawn to nucleic acids encoding independent and distinct polypeptides set forth in SEQ ID NOS:127-229 and 269-280, classified in class 536, subclass 23.5.

Inventions 117-233.

Claims 15-22, 25 and 26, drawn to independent and distinct polypeptides set forth in SEQ ID NOS:127-229 and 269-280, classified in class 530, subclass 350.

Inventions 1-116 are related as products which share an alleged common utility of pathogenic virulence but the common utility is not linked to a substantial structural feature. The products in this relationship are distinct if either or both of the following can be shown: (1) that the products encompass embodiments that are not required to perform the common utility or (2) that the products as claimed can be used to perform another utility. In this case, the products can be used to detect the microorganism, diagnose an infection or produce the protein to make the antibody.

Inventions 117-233 are related as products which share an alleged common utility of pathogenic virulence but the common utility is not linked to a substantial structural feature. The products in this relationship are distinct if either or both of the following can be shown: (1) that the products encompass embodiments that are not required to perform the common utility or (2) that the products as claimed can be used to perform another utility. In this case, the products can be used as a vaccine, used to make an antibody in vitro, used diagnose an infection, screen for active immunity, or screen for chemicals for inhibiting virulence activity.

Application/Control Number: 10/660,811

Art Unit: 1645

The inventions are distinct, each from the other because of the following reasons:

Because these inventions are independent or distinct for the reasons given above and have acquired a separate status in the art in view of their different classification, restriction for examination purposes as indicated is proper.

Because these inventions are independent or distinct for the reasons given above and the inventions require a different field of search (see MPEP § 808.02), restriction for examination purposes as indicated is proper.

Because these inventions are independent or distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or

Application/Control Number: 10/660,811

Art Unit: 1645

more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patricia A. Duffy whose telephone number is 571-272-0855. The examiner can normally be reached on M-Th 6:30 pm - 6:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Smith Lynette can be reached on 571-272-0864. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Patricia A. Duffy

Page 4

Primary Examiner

Art Unit 1645